Gould Asset Management LLC CA Sells 130 Shares of Abbott Laboratories (NYSE:ABT)

Gould Asset Management LLC CA lessened its holdings in shares of Abbott Laboratories (NYSE:ABT) by 2.9% during the 4th quarter, Holdings Channel reports. The firm owned 4,427 shares of the healthcare product maker’s stock after selling 130 shares during the period. Gould Asset Management LLC CA’s holdings in Abbott Laboratories were worth $487,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABT. Newbridge Financial Services Group Inc. increased its stake in Abbott Laboratories by 65.3% in the 3rd quarter. Newbridge Financial Services Group Inc. now owns 762 shares of the healthcare product maker’s stock worth $74,000 after acquiring an additional 301 shares during the last quarter. Exchange Traded Concepts LLC boosted its holdings in shares of Abbott Laboratories by 147.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 31,159 shares of the healthcare product maker’s stock worth $3,018,000 after purchasing an additional 18,546 shares during the period. Strategic Blueprint LLC increased its position in shares of Abbott Laboratories by 3.6% during the 3rd quarter. Strategic Blueprint LLC now owns 8,235 shares of the healthcare product maker’s stock valued at $798,000 after purchasing an additional 286 shares during the last quarter. Syntegra Private Wealth Group LLC increased its position in shares of Abbott Laboratories by 4.7% during the 3rd quarter. Syntegra Private Wealth Group LLC now owns 12,575 shares of the healthcare product maker’s stock valued at $1,218,000 after purchasing an additional 562 shares during the last quarter. Finally, SS&H Financial Advisors Inc. bought a new position in shares of Abbott Laboratories during the 3rd quarter valued at approximately $2,805,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE ABT remained flat at $106.89 during mid-day trading on Thursday. The company had a trading volume of 3,111,313 shares, compared to its average volume of 5,687,034. The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $185.47 billion, a PE ratio of 33.30, a price-to-earnings-growth ratio of 2.59 and a beta of 0.74. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64. The business has a 50-day simple moving average of $113.77 and a 200-day simple moving average of $107.96.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The firm had revenue of $9.96 billion during the quarter, compared to analysts’ expectations of $9.88 billion. During the same period in the prior year, the business posted $1.03 EPS. The firm’s quarterly revenue was up 2.2% on a year-over-year basis. On average, equities analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.06%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Insider Buying and Selling at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now directly owns 18,760 shares of the company’s stock, valued at $2,223,060. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrea F. Wainer sold 12,500 shares of the firm’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $120.00, for a total value of $1,500,000.00. Following the sale, the executive vice president now directly owns 78,704 shares in the company, valued at $9,444,480. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,435 shares of company stock worth $6,451,298. 1.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ABT. Royal Bank of Canada cut their target price on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Evercore ISI boosted their target price on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Citigroup boosted their target price on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Barclays cut their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday. Finally, Raymond James reaffirmed a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.50.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.